Seeking Alpha

Salix Pharmaceuticals (SLXP +2%) trades higher after beating bottom line Q2 estimates yesterday....

Salix Pharmaceuticals (SLXP +2%) trades higher after beating bottom line Q2 estimates yesterday. Net profit rose 4.6% as the drug developer saw continued strength in sales of its Xifaxan tablets. The company also raised its FY12 outlook to $2.86 per share, up from its previous view of $2.59 a share, reflecting its March placement of $690M in senior notes.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs